62 related articles for article (PubMed ID: 17294720)
1. [Establishment of an imatinib resistance cell line K562R and its resistant principia].
Zhu HL; Liu T; Meng WT; Jia YQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jan; 38(1):22-6. PubMed ID: 17294720
[TBL] [Abstract][Full Text] [Related]
2. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
3. An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Xing H; Liu T; Meng W; Gong Y
Int J Lab Hematol; 2011 Apr; 33(2):176-81. PubMed ID: 20942869
[TBL] [Abstract][Full Text] [Related]
4. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
5. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
7. [Establishment of an imatinib resistant cell line K562/G01 and its characterization].
Qi J; Peng H; Gu ZL; Liang ZQ; Yang CZ
Zhonghua Xue Ye Xue Za Zhi; 2004 Jun; 25(6):337-41. PubMed ID: 15308010
[TBL] [Abstract][Full Text] [Related]
8. Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells.
Mlejnek P; Dolezel P; Faber E; Kosztyu P
Ann Hematol; 2011 Jul; 90(7):837-42. PubMed ID: 21225261
[TBL] [Abstract][Full Text] [Related]
9. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
10. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
[TBL] [Abstract][Full Text] [Related]
11. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
[TBL] [Abstract][Full Text] [Related]
12. [Effect of trichostatin alone and combination with imatinb on the proliferation and apoptosis of the K562R cells].
Chen S; Liu Y; Zeng H; He Q; Zhao X; Chen F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 36(8):782-5. PubMed ID: 21937807
[TBL] [Abstract][Full Text] [Related]
13. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
[TBL] [Abstract][Full Text] [Related]
14. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
15. [Effect of phenylhexyl isothiocyanate on drug-resistance to imatinib in K562/G01 cell line].
Wu RJ; Huang YQ; Ma XD
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):149-52. PubMed ID: 23611223
[TBL] [Abstract][Full Text] [Related]
16. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
Nambu T; Araki N; Nakagawa A; Kuniyasu A; Kawaguchi T; Hamada A; Saito H
Cancer Sci; 2010 Jan; 101(1):137-42. PubMed ID: 19843070
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.
Ito T; Tanaka H; Kimura A
Eur J Haematol; 2007 May; 78(5):417-31. PubMed ID: 17432977
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
[TBL] [Abstract][Full Text] [Related]
19. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
